Hims & Hers (HIMS) announced access to Eli Lilly (LLY) GLP-1 products through its platform, expanding its weight-loss offering, though its exact role and profit share in the arrangement remains unclear beyond required membership participation, Leerink tells investors in a research note. While the news is likely to support the stock in the near term, limited visibility into the economic benefits leads to a maintained Market Perform rating ahead of further details expected on the upcoming call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers enables Zepbound vials, KwikPen prescribing through LillyDirect
- Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in?
- Balanced Risk/Reward Amid Peptide-Driven Rally and Regulatory Uncertainty
- Hims & Hers price target raised to $30 from $25 at BofA
- Amazon (AMZN) Steps Up Weight Loss Push, Knocks HIMS Stock Off the Scale